When Ira Mellman joined Genentech in 2007, the cancer immunotherapy revolution had not yet begun. Only in 2008 did Medarex unveil the first phase I data from its PD1 blocker MDX-1106, later to become Bristol Myers Squibb’s nivolumab (Opdivo). As follow-up data started hinting at profound and lasting therapeutic effects for these agents, everyone piled in and the race began.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Interviewed by Asher Mullard
The interview was edited for length and clarity.
